ALDER BIOPHARMACEUTICALS INC's ticker is ALDR and the CUSIP is 014339105. A total of 150 filers reported holding ALDER BIOPHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is 24.50 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $466,000 | -19.0% | 39,629 | -5.8% | 0.00% | -100.0% |
| Q1 2019 | $575,000 | +49.7% | 42,081 | +12.0% | 0.00% | – |
| Q4 2018 | $384,000 | +4.1% | 37,575 | +69.9% | 0.00% | – |
| Q3 2018 | $369,000 | +5.7% | 22,110 | 0.0% | 0.00% | – |
| Q2 2018 | $349,000 | +24.2% | 22,110 | 0.0% | 0.00% | – |
| Q1 2018 | $281,000 | +11.1% | 22,110 | 0.0% | 0.00% | – |
| Q4 2017 | $253,000 | -6.6% | 22,110 | 0.0% | 0.00% | – |
| Q3 2017 | $271,000 | +8.4% | 22,110 | +6.2% | 0.00% | – |
| Q2 2017 | $250,000 | -43.3% | 20,810 | -1.4% | 0.00% | – |
| Q1 2017 | $441,000 | -38.0% | 21,100 | -38.2% | 0.00% | -100.0% |
| Q4 2016 | $711,000 | -68.9% | 34,161 | -51.7% | 0.00% | -50.0% |
| Q3 2016 | $2,288,000 | +52.3% | 70,698 | +17.5% | 0.00% | 0.0% |
| Q2 2016 | $1,502,000 | +205.3% | 60,167 | +199.2% | 0.00% | +100.0% |
| Q1 2016 | $492,000 | -23.6% | 20,112 | +5.5% | 0.00% | 0.0% |
| Q4 2015 | $644,000 | +3.0% | 19,070 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $625,000 | -47.7% | 19,070 | -15.5% | 0.00% | 0.0% |
| Q2 2015 | $1,196,000 | – | 22,570 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 229,895 | $7,593,000 | 6.73% |
| Foresite Capital Management II, LLC | 419,997 | $13,873,000 | 4.65% |
| Cormorant Asset Management, LP | 757,475 | $25,019,000 | 2.99% |
| NEXTHERA CAPITAL LP | 60,000 | $1,982,000 | 2.81% |
| SENZAR ASSET MANAGEMENT, LLC | 557,170 | $18,403,325,000 | 2.05% |
| Parametrica Management Ltd | 9,360 | $309,000 | 2.04% |
| Partner Investment Management, L.P. | 36,756 | $1,214,000 | 1.99% |
| PFM Health Sciences, LP | 1,890,030 | $62,428,000 | 1.90% |
| PYRRHO CAPITAL MANAGEMENT, LP | 63,000 | $2,081,000 | 1.40% |
| BB BIOTECH AG | 1,510,150 | $49,880,000 | 1.40% |